Perhaps an even more surefire way to land on the far side of that threshold is to tell them about your trip on one of the ...

THE SPIRIT MOLECULE weaves an account of Dr. Rick Strassman's groundbreaking DMT research through a multifaceted approach to this intriguing hallucinogen found in the human brain and hundreds of ...

An outlandish experiment searching for a brain network that tunes up and down the feeling of immersion is hoping to unlock the therapeutic effects of psychedelics ...

Cybin is also developing CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder. It reports that the phase 2 results of its CYB004 anxiety treatment drug study are set for ...

It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized ...

One goal of the company is to optimize the pharmacokinetics and bioavailability of DMT, as the molecule itself is quickly metabolized. Small Pharma is researching DMT analogues, replacing specific ...

The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for ...

“The first thing biomedical researchers started to do was try to purify it and transform ayahuasca into a molecule of DMT and give it to people to try to minimize the side effects, like nausea,” ...

Participants will be given the drug DMT, followed by talking therapy ... The drug is known as the "spirit molecule" because of the way it alters the human consciousness and produces hallucinations ...

The DMT method uses dimethyl terephthalic acid ... cyclohexane dimethanol (CHDM). This molecule is much larger than the compact ethylene glycol, but undergoes transesterification in much the ...

By contrast, DMT exhibits a comparatively more rapid onset ... harness artificial intelligence (AI), ‘big data’ and small-molecule therapy (SMT). For example, atai’s drug-development ...